Long-term dupilumab benefits adolescents with eczema

October 09, 2019

Results from a phase IIa open-label trial and a subsequent phase III open-label extension trial reinforce findings from an earlier short-term trial that adolescents with moderate-to-severe atopic dermatitis, or eczema, can experience significant improvements with dupilumab. The results from these latest studies, which are reported in the British Journal of Dermatology, demonstrate the long-term safety and efficacy of the medication for up to 52 weeks of treatment.

Dupilumab works by stopping the action of certain substances in the body that cause the symptoms of eczema. Specifically, it is a monoclonal antibody against interleukin-4 receptor alpha.

"Adolescents with moderate-to-severe atopic dermatitis have a high disease burden that negatively affects quality of life, and patients are in need of therapies that can be used long-term," said senior author Ashish Bansal, MD, of Regeneron Pharmaceuticals, Inc., in Tarrytown, New York. "Results from these trials show that dupilumab provides substantial and sustained clinical benefit to these patients with an acceptable safety profile."
-end-


Wiley

Related Eczema Articles from Brightsurf:

Vitamin D lessens symptoms of severe eczema in children
Vitamin D supplementation eased the symptoms experienced by children with severe atopic dermatitis, or eczema, in a recent randomized controlled trial published in Pharmacology Research & Perspectives.

TV ads for psoriasis and eczema medications portray few people of color
Commercials from pharmaceutical companies advertising medication to treat psoriasis and eczema lack people from racial and ethnic minorities, according to research from the Perelman School of Medicine at the University of Pennsylvania.

NIH-supported scientists demonstrate how genetic variations cause eczema
New research supported by the National Institutes of Health delineates how two relatively common variations in a gene called KIF3A are responsible for an impaired skin barrier that allows increased water loss from the skin, promoting the development of atopic dermatitis, commonly known as eczema.

Biomedical researchers get closer to why eczema happens
A new study from researchers at Binghamton University, State University of New York may help to peel back the layers of unhealthy skin -- at least metaphorically speaking -- and get closer to a cure.

Researchers uncover novel approach for treating eczema
Researchers at the University of British Columbia (UBC) and Vancouver Coastal Health Research Institute (VCHRI) have identified a key enzyme that contributes to eczema, which may lead to better treatment to prevent the skin disorder's debilitating effects.

Revving up immune system may help treat eczema
Studying eczema, researchers at Washington University School of Medicine in St.

Childhood eczema cannot be prevented by daily moisturiser use, study finds
Using moisturisers on newborn babies does not prevent eczema as previously thought, according to a major new study.

Atopic eczema linked to increase fracture risk in adults
Adults with atopic eczema could face a raised risk of fracture, with the risk increasing the more severe the condition, according to a new study published in the Journal of Allergy and Clinical Immunology.

Long-term dupilumab benefits adolescents with eczema
Results from a phase IIa open-label trial and a subsequent phase III open-label extension trial reinforce findings from an earlier short-term trial that adolescents with moderate-to-severe atopic dermatitis, or eczema, can experience significant improvements with dupilumab.

Multiple genes affect risk of asthma, hay fever and eczema
In a new study from SciLifeLab at Uppsala University, researchers have found a total of 141 regions (genes) in our genetic material that largely explain the genetic risk underlying asthma, hay fever and eczema.

Read More: Eczema News and Eczema Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.